OnKure Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 12, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 12, 2026

OKUR$3.39+6.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

(In thousands)

	Years Ended December 31,
	2025	2024
(in thousands)
Cash flows from operating activities:
Net loss	$(59,517)	$(52,673)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	11,633	4,530
Depreciation and amortization	447	459
Amortization of right-of-use asset - operating	383	203
Loss on disposal of property and equipment	6	—
Amortization of debt issuance costs	—	142
Non-cash interest expense	—	120
Loss on sales of available-for-sale securities	—	54
Change in operating assets and liabilities:
Prepaid and other assets	289	2,256
Accounts payable, accrued and other liabilities	(4,545)	(5,927)
Lease liabilities	(536)	(281)
Other long-term liabilities	12	—
Net cash used in operating activities	(51,828)	(51,117)
Cash flows from investing activities:
Proceeds from sales of marketable securities	—	15,925
Purchases of property and equipment	(46)	(52)
Net cash (used in) provided by investing activities	(46)	15,873
Cash flows from financing activities:
Proceeds from the issuance of common stock in Concurrent Financing	—	58,881
Payment of issuance costs associated with the Concurrent Financing	(37)	(4,327)
Cash acquired in connection with the reverse recapitalization	—	57,736
Payment of reverse recapitalization transaction costs	(40)	(2,045)
Proceeds from issuance of convertible notes payable	—	6,000
Payment of issuance costs associated with the issuance of convertible notes payable	—	(142)
Proceeds from sale of stock under the employee stock purchase plan	240	—
Proceeds from the issuance of common stock for exercises of stock options	—	26
Net cash provided by financing activities	163	116,129
Net decrease in cash and cash equivalents	(51,711)	80,885
Cash and cash equivalents, beginning of period	110,761	29,876
Cash and cash equivalents, end of period	$59,050	$110,761
Supplemental cash flow information:
Interest paid	$—	$—
Supplemental disclosure of noncash investing activities:
Conversion of Series C Preferred Stock	$—	$129,825
Conversion of convertible note payable	$—	$6,120
Assets acquired in connection with the reverse recapitalization	$—	$17,222
Other liabilities assumed in connection with the reverse recapitalization	$—	$9,459
Reverse recapitalization transaction costs included in accounts payable	$—	$40
Concurrent Financing issuance costs included in accounts payable	$—	$37
Concurrent Financing issuance costs paid by Reneo prior to Merger	$—	$89

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.